Literature DB >> 32540433

Targeting post-translational modification of transcription factors as cancer therapy.

Meijia Qian1, Fangjie Yan1, Tao Yuan1, Bo Yang1, Qiaojun He2, Hong Zhu3.   

Abstract

Dysregulated transcription factors (TFs) fuel aberrant gene expression networks, resulting in cell overproliferation, migration, and immunosuppression. Given that TFs are regarded to have vital roles in tumors, various approaches are exploited to modulate their activities. Nevertheless, except for some ligand-binding nuclear receptors, most TFs are still considered 'undruggable' targets. Responding to extra- or intracellular stimuli, TFs are decorated with an array of post-translational modifications (PTMs) to regulate their subcellular localizations, protein-protein/DNA interactions, and stability. These PTMs orchestrate the multiple functions of TFs, thus offering numerous potential targets. In this review, we systematically review emerging concepts and effective agents in PTMs-associated TF-targeting, which could provide paradigms for cancer treatment.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32540433     DOI: 10.1016/j.drudis.2020.06.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  10 in total

Review 1.  Post-translational modifications in tumor-associated carbonic anhydrases.

Authors:  Anna Di Fiore; Claudiu T Supuran; Andrea Scaloni; Giuseppina De Simone
Journal:  Amino Acids       Date:  2021-08-26       Impact factor: 3.520

Review 2.  Compendium of human transcription factor effector domains.

Authors:  Luis F Soto; Zhaorong Li; Clarissa S Santoso; Anna Berenson; Isabella Ho; Vivian X Shen; Samson Yuan; Juan I Fuxman Bass
Journal:  Mol Cell       Date:  2021-12-03       Impact factor: 17.970

3.  MIMAS: microfluidic platform in tandem with MALDI mass spectrometry for protein quantification from small cell ensembles.

Authors:  Jorvani Cruz Villarreal; Rory Kruithoff; Ana Egatz-Gomez; Paul D Coleman; Robert Ros; Todd R Sandrin; Alexandra Ros
Journal:  Anal Bioanal Chem       Date:  2022-04-06       Impact factor: 4.478

Review 4.  Current strategies and progress for targeting the "undruggable" transcription factors.

Authors:  Jing-Jing Zhuang; Qian Liu; Da-Lei Wu; Lu Tie
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

5.  Quantitative Approach for Protein Analysis in Small Cell Ensembles by an Integrated Microfluidic Chip with MALDI Mass Spectrometry.

Authors:  Mian Yang; Jorvani Cruz Villarreal; Nethmi Ariyasinghe; Rory Kruithoff; Robert Ros; Alexandra Ros
Journal:  Anal Chem       Date:  2021-04-05       Impact factor: 6.986

Review 6.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

7.  Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.

Authors:  Meijia Qian; Fangjie Yan; Weihua Wang; Jiamin Du; Tao Yuan; Ruilin Wu; Chenxi Zhao; Jiao Wang; Jiabin Lu; Bo Zhang; Nengming Lin; Xin Dong; Xiaoyang Dai; Xiaowu Dong; Bo Yang; Hong Zhu; Qiaojun He
Journal:  Acta Pharm Sin B       Date:  2021-06-25       Impact factor: 11.413

Review 8.  Noncoding RNAs as sensors of tumor microenvironmental stress.

Authors:  Yue Lv; Yinghao Lv; Zhen Wang; Kefei Yuan; Yong Zeng
Journal:  J Exp Clin Cancer Res       Date:  2022-07-16

9.  Integrated analysis to study the interplay between post-translational modifications (PTM) in hepatitis C virus proteins and hepatocellular carcinoma (HCC) development.

Authors:  Aqsa Ikram; Bisma Rauff; Badr Alzahrani; Faryal Mehwish Awan; Ayesha Obaid; Anam Naz; Salik Javed Kakar; Hussnain Ahmed Janjua
Journal:  Sci Rep       Date:  2022-09-19       Impact factor: 4.996

10.  Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.

Authors:  Guoshun Luo; Zhenbang Li; Xin Lin; Xinyu Li; Yu Chen; Kun Xi; Maoxu Xiao; Hanlin Wei; Lizhe Zhu; Hua Xiang
Journal:  Acta Pharm Sin B       Date:  2020-11-06       Impact factor: 11.413

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.